RECRUITING

Study of How People Make Decisions About Prostate Cancer Risk

Talk to us

Conditions

High Risk Prostate CancerPolygenic Risk ModifiersBRCA1/2 Mutation CarriersAssessments

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how people make choices about their health care, including about methods to screen for prostate cancer. Researchers are also doing this study to learn about how the genetic risk modifier test affects people's thoughts and feelings.

Official Title

Effect of Polygenic Risk Modifiers on Decisions of BRCA1/2 Mutation Carriers at Risk for Prostate Cancer

Quick Facts

Study Start:2025-09-25
Study Completion:2027-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07197723

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 70 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Documentation of Disease
  2. * Age between 40 - 70;
  3. * Assigned male sex at birth
  4. * Completed full sequence or targeted genetic testing with a result confirmed in a clinically approved laboratory showing a BRCA1/2 likely pathogenic or pathogenic variant identified
  5. * English-fluent; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.
  1. * Major psychiatric illness or cognitive impairment that in the judgment of the study investigators or study staff would preclude study participation.
  2. * Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff.
  3. * Under active treatment for a malignancy. (Patients are eligible if they have a prior history of malignancy other than prostate cancer, as long as they are not currently undergoing active treatment for the malignancy)

Contacts and Locations

Study Contact

Jada Hamiliton, PhD, MPH
CONTACT
646-888-0049
hamiltoj@mskcc.org
Kenneth Offit, MD
CONTACT
646-888-4050

Principal Investigator

Jada Hamilton, PhD, MPH
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Jada Hamilton, PhD, MPH, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-09-25
Study Completion Date2027-09

Study Record Updates

Study Start Date2025-09-25
Study Completion Date2027-09

Terms related to this study

Keywords Provided by Researchers

  • Polygenic Risk Modifiers
  • BRCA1/2 Mutation Carriers
  • Assessments

Additional Relevant MeSH Terms

  • High Risk Prostate Cancer